PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates
Podcast: Can we improve FH detectionListen
Hot off the Press A critical appraisal of PCSK9 inhibitors: PCSK9 monoclonal antibodies versus small interfering RNA

Hot Topics

From the 21st Closed Scientific Expert Meeting of the Editorial Board

Alan RemaleyLDL binding to the LDL receptor: Structural insights
 
Alan Remaley

Watch now
Catherine BoileauLipid and lipoprotein genes: More data, more complexity and more uncertainties
Catherine Boileau

Watch now
Michelle O'DonoghueVery low LDL-C: Long-term prospective findings
 
Michelle O'Donoghue

Watch now

Slide Resource Programme

Downloadable slide resource programme Find out more »

Expert Views

PlayVerve-101: Where are we up to with PCSK9 gene editing?
Verve-101: Where are we up to with PCSK9 gene editing?
PlayLepodisiran: What progress towards Lp(a) reduction?
Apo(a) size and PAD revascularisation outcomes: What’s the link?
PlayLepodisiran: What progress towards Lp(a) reduction?
Lepodisiran: What progress towards Lp(a) reduction?

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

Most viewed
Most viewed
VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

From the Editors

Lerodalcibep: What does LIBerate-HeFH tell us?

Prof Derick RaalProfessor Derick Raal discusses lerodalcibep data from the LIBerate-HeFH trial and explains what the results mean to practising clinicians.

Read the editorial

Lerodalcibep

Related content:

LIBerate-HeFH: Lerodalcibep reduces LDL-C in HeFH

Congress Highlights

ACC.25 Banner

News from ACC 2025

See all reports »

Upcoming Events

In Case You Missed It

Derrick Raal
PCSK9 inhibition with a novel fusion protein

Derick Raal, University of the Witwatersrand, Johannesburg, South Africa, presents efficacy and safety data from Phase 3 trials of lerodalcibep.

Christie Ballantyne
Oral PCSK9 inhibition: Clinical update

Christie Ballantyne, Baylor College of Medicine, Houston, USA, reports Phase 2b results with the oral PCSK9 inhibitor, MK-0616.

News from ESC 2024

ESC 2024 Banner
View ESC 24 reports »

About PCSK9 Education and Research Forum

The independent resource on PCSK9 science and its translation into critically important new treatments to lower LDL-C, which promise to transform the prognosis of patients with hypercholesterolaemia, accelerated atherosclerotic vascular heart disease and a high risk of premature CV death and disability.
Read more »

Increasing awareness, knowledge and understanding of elevated serum TGs in the development of CVD and pancreatitis.

JOIN TODAY

Developing knowledge and understanding of Lp(a) as an independent risk factor for ASCVD and aortic valve stenosis.

JOIN TODAY

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the Sorbonne University Prof Henry GinsbergIrving Professor of Medicine, Columbia University Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved